RUNX3 and cancer: As might be expected, if RUNX3 were behaving as a tumour suppressor, the decreased expression of this protein in gastric (Wei et al, 2005), lung (Araki et al, 2005) and oesophageal (Sakakura et al, 2007) cancers has been associated with worse patient outcome.